In contrast, SGLT2 inhibitors—now widely adopted in cardiovascular medicine—demonstrate favorable effects on NLRP3 suppression, atrial structural remodeling, and arrhythmia prevention, particularly in patients with diabetes or heart failure. This evidence concerns the gene NLRP3 and diabetes mellitus.